Monoclonal antibodies in targeted therapy;Przeciwciała monoklonalne w terapii celowanej

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 66, Issue , 2012, Pages 663-673

  Powroźnik, Beata ^a   Kubowicz, Paulina ^a   Pȩkala, Elzbieta ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Biological drugs; Molecular target; Monoclonal antibodies; Targeted therapy

Indexed keywords

EID: 84867949782     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: 10.5604/17322693.1009980     Document Type: Review

References (68)

1. Adler R. A., Gill R. S.: Clinical utility of denosumab for treatment of bone loss in men and women. Clin. Interv. Aging, 2011;6:119-124
2. Antoniak K., Nowak J. Z.: Bewacizumab - postȩp w leczeniu nowotworów z przerzutami i nadzieja pacjentów z retinopatia̧ proliferacyjna̧. Postȩpy Hig. Med. Dośw., 2007;61:320-330
3. Boehncke W. H.: Efalizumab in the treatment of psoriasis. Biologics, 2007;1:301-309
4. Borysowski J., Górski A.: Zastosowanie metody phage display w eksperymentalnej terapii onkologicznej. Postȩpy Hig. Med. Dośw., 2004;58:100-107
5. Brandes D. W., Shaya F. T., Pill M. W.: Quantifying the role of natalizumab in health and economic outcomes in multiple sclerosis. Am. J. Manag. Care, 2010;16(Suppl.6):S171-S177
6. Breedveld F. C., Weisman M. H., Kavanaugh A. F., Cohen S. B., Pavelka K., van Vollenhoven R., Sharp J., Perez J. L., Spencer-Green G. T.: The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum., 2006;54:26-37
7. Bryan J., Borthakur G.: Role of rituximab in first-line treatment of chronic lymphocytic leukemia. Ther. Clin. Risk Manag., 2010;7:1-11
8. Busse W., Corren J., Lanier B. Q., McAlary M., Fowler-Taylor A., Cioppa G. D., van As A., Gupta N.: Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J. Allergy Clin. Immunol., 2001;108:184-190
9. Carnahan J., Stein R., Qu Z., Hess K., Cesano A., Hansen H. J., Goldenberg D. M.: Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol. Immunol., 2007;44:1331-1341
10. Chan A. C., Carter P. J.: Therapeutic antibodies for autoimmunity and inflammation. Nat. Rev. Immunol., 2010;10:301-316
11. Colombel J. F., Sandborn W. J., Rutgeerts P., Enns R., Hanauer S. B., Panaccione R., Schreiber S., Byczkowski D., Li J., Kent J. D., Pollack P. F.: Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology, 2007;132:52-65
12. Cottone M., Criscuoli V.: Infliximab to treat Crohn's disease: an update. Clin. Exp. Gastroenterol., 2011;4:227-238
13. Coyle P. K.: The role of natalizumab in the treatment of multiple sclerosis. Am. J. Manag. Care, 2010;16(Suppl.6):S164-S170
14. Croom K. F., McCormack P. L.: Adalimumab: in plaque psoriasis. Am. J. Clin. Dermatol., 2009;10:43-50
15. Cummings S. R., San Martin J., McClung M. R., Siris E. S., Eastell R., Reid I. R., Delmas P., Zoog H. B., Austin M., Wang A., Kutilek S., Adami S., Zanchetta J., Libanati C., Siddhanti S., Christiansen C.: Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med., 2009;361:756-765
16. Emery P., Keystone E., Tony H. P., Cantagrel A., van Vollenhoven R., Sanchez A., Alecock E., Lee J., Kremer J.: IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann. Rheum. Dis., 2008;67, 1516-1523
17. Fakih M., Wong R.: Effcacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer. Curr. Oncol., 2010;17(Suppl.1):S3-S17
18. Hanauer S. B., Feagan B. G.: Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet, 2002;359:1541-1549
19. Hanauer S. B., Sandborn W. J., Rutgeerts P., Fedorak R. N., Lukas M., MacIntosh D., Panaccione R., Wolf D., Pollack P.: Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology, 2006;130:323-333
20. Heinemann V., Stintzing S., Kirchner T., Boeck S., Jung A.: Clinical relevance of EGFR-and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treat. Rev., 2009;35:262-271
21. Jenerowicz D.: Terapia biologiczna w wybranych chorobach skóry. Przew. Lek., 2006;7:92-99
22. Kaczmarek-Borowska B., Trelińska-Nowosad T., Karolewski K., Jóźwik P.: Leczenie celowane w raku jajnika - na jakim etapie jesteśmy? Współczesna Onkologia, 2007;11:492-497
23. Keystone E., Genovese M., Klareskog L., Hsia E. C., Hall S., Miranda P. C., Pazdur. J, Bae S. C., Palmer W., Xu S., Rahman M. U.: Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann. Rheum. Dis., 2010;69:1129-1135
24. Keystone E., Heijde D., Mason D. Jr., Landewé R., Vollenhoven R. V., Combe B., Emery P., Strand V., Mease P., Desai C., Pavelka K.: Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum., 2008;58:3319-3329
25. Kieć-Kononowicz K.: Terapeutyczne przeciwciała monoklonalne i białka fuzyjne zawieraja̧ce ich elementy. Farmacja Polska, 2007;63(5):183-198
26. Kozuch P. L., Hanauer S. B.: Kozuch P. L., Hanauer S. B.: Treatment of infammatory bowel disease: a review of medical therapy. World J. Gastroenterol., 2008;14:354-377
27. Kufer P., Lutterbüse R., Baeuerle P. A.: A revival of bispecific antibodies. Trends Biotechnol., 2004;22:238-244
28. Lewiecki E. M., Bilezikian J. P.: Denosumab for the treatment of osteoporosis and cancer-related conditions. Clin. Pharmacol. Ther., 2012;91:123-133
29. Lichtenstein G. R., Yan S., Bala M., Blank M., Sands B. E.: Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology, 2005;128:862-869
30. Lievre A., Bachet J. B., Boige V., Cayre A., Le Corre D., Buc E., Ychou M., Bouché O., Landi B., Louvet C., André T., Bibeau F., Diebold M. D., Rougier P., Ducreux M., Tomasic G., Emile J. F., Penault-Llorca F., Laurent-Puig P.: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol., 2008;26:374-379
31. Linenberger M. L., Maloney D. G., Bernstein I. D.: Antibody-directed therapies for hematological malignancies. Trends Mol. Med., 2002;8:69-76
32. Loertscher R.: The utility of monoclonal antibody therapy in renal transplantation. Transplant. Proc., 2002;34:797-800
33. Long A. A.: Monoclonal antibodies and other biologic agents in the treatment of asthma. MAbs, 2009:1:237-246
34. Maini R. N., Taylor P. C., Szechinski J., Pavelka K., Bröll J., Balint G., Emery P., Raemen F., Petersen J., Smolen J., Thomson D., Kishimoto T.: Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum., 2006;54:2817-2829
35. Malviya G., Conti F., Chianelli M., Scopinaro F., Dierckx R. A., Signore A.: Molecular imaging of rheumatoid arthritis by radiolabelled monoclonal antibodies: new imaging strategies to guide molecular therapies. Eur. J. Nucl. Med. Mol. Imaging, 2010;37:386-398
36. Marble D. J., Gordon K. B., Nickoloff B. J.: Targeting TNFa rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation. J. Dermatol. Sci., 2007;48:87-101
37. Martin D. F., Maguire M. G.: Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med., 2011;364:1897-1908
38. McLaughlin P., Grillo-López A. J., Link B. K., Levy R., Czuczman M. S., Williams M. E., Heyman M. R., Bence-Bruckler I., White C. A., Cabanillas F., Jain V., Ho A. D., Lister J., Wey K., Shen D., Dallaire B. K.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol., 1998;16:2825-2833
39. Motta G., Cea M., Moran E., Carbone F., Augusti V., Patrone F., Nencioni A.: Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives. Clin. Dev. Immunol., 2010;2010:428253
40. Mueller X. M.: Drug immunosuppression therapy for adult heart transplantation. Part 1: immune response to allograft and mechanism of action of immunosuppressants. Ann. Thorac. Surg., 2004;77:354-362
41. Narbutt J., Lesiak A., Sysa-Jȩdrzejowska A., Szepietowski J.: Inhibitory TNF-a w leczeniu łuszczycy zwyczajnej i łuszczycowego zapalenia stawów: dobór pacjenta i monitorowanie terapii. Dermatologia Kliniczna, 2009;11:226-236
42. Nelson A. L., Dhimolea E., Reichert J. M.: Development trends for human monoclonal antibody therapeutics. Nat. Rev. Drug Discov., 2010;9:767-774
43. Nowak J. Z., Bienias W.: Zwyrodnienie plamki zwia̧zane z wiekiem (AMD): etiopatogeneza i strategie terapeutyczne. Postȩpy Hig. Med. Dośw., 2007;61:83-94
44. Pachmann K., Camara O., Kroll T., Gajda M., Gellner A. K., Wotschadlo J., Runnebaum I. B.: Effcacy control of therapy using circulating epithelial tumor cells (CETC) as "liquid biopsy": trastuzumab in HER2/neu-positive breast carcinoma. J. Cancer Res. Clin. Oncol., 2011;137:1317-1327
45. Pelaia G., Gallelli L., Renda T., Romeo P., Busceti M. T., Grembiale R. D., Maselli R., Marsico S. A., Vatrella A.: Update on optimal use of omalizumab in management of asthma. J. Asthma Allergy, 2011;4:49-59
46. Reichert J. M.: Antibody-based therapeutics to watch in 2011. MAbs, 2011;3:76-99
47. Revicki D. A., Willian M. K., Menter A., Gordon K. B., Kimball A. B., Leonardi C. L., Langley R. G., Kimel M., Okun M.: Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J. Dermatol. Treat., 2007;18:34-350
48. Rutgeerts P. J., Mellili L. E., Li J., Pollack P. F.: Adalimumab maintains improvement in inflammatory bowel disease questionnaire (IBDQ) scores over 1 year following the initial attainment of remisssion in patients with moderately severely active Crohn's disease: results of the CLASSIC II study. Gastroenterology, 2006;130:A479
49. Santini D., Pantano F., Vincenzi B., Loupakis F., Caraglia M., Falcone A., Tonini G.: Molecular predictive factors of response to anti-EGFR antibodies in colorectal cancer patients. Eur. J. Cancer, 2008;6(Suppl.):86-90
50. Schön M. P.: Efalizumab in the treatment of psoriasis: mode of action, clinical indications, efficacy, and safety. Clin. Dermatol., 2008;26:509-514
51. Sievers E. L., Larson R. A., Stadtmauer E. A., Estey E., Löwenberg B., Dombret H., Karanes C., Theobald M., Bennett J. M., Sherman M. L., Berger M. S., Eten C. B., Loken M. R., van Dongen J. J., Bernstein I. D., Appelbaum F. R.: Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J. Clin. Oncol., 2001;19:3244-3254
52. Skoczek M., Grela-Wojewoda A., Rolski J.: Terapia celowana Czȩść II. Zastosowanie kliniczne leków hamuja̧cych aktywność kinazy tyrozynowej - przeciwciała monoklonalne. Współczesna Onkologia, 2008;12:363-369
53. Smolen J. S., Emery P.: Infliximab: 12 years of experience. Arthritis Res. Ther., 2011;13(Suppl.1):S2
54. Smolen J. S., Kay J., Doyle M. K., Landewé R., Matteson E. L., Wollenhaupt J., Gaylis N., Murphy F. T., Neal J. S., Zhou Y., Visvanathan S., Hsia E. C., Rahman M. U.: Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor a inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet, 2009;374:210-221
55. Smolen J., Landewé R. B., Mease P., Brzezicki J., Mason D., Luijtens K., van Vollenhoven R. F., Kavanaugh A., Schiff M., Burmester G. R., Strand V., Vencovsky J., van der Heijde D.: Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. Ann. Rheum. Dis., 2009;68:797-804
56. Soler M., Matz J., Townley R., Buhl R., O'Brien J., Fox H., Thirlwell J., Gupta N., Della Cioppa G.: The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur. Respir. J., 2001;18:254-261
57. Sosińska-Mielcarek K., Jassem J.: Przeciwciała monoklonalne w leczeniu nowotworów litych. Onkologia w Praktyce Klinicznej, 2005;1:225-232
58. Strunk R. C., Bloomberg G. R.: Omalizumab for asthma. N. Engl. J. Med., 2006;354:2689-2695
59. Szmyrka-Kaczmarek M., Wiland P.: Tocilizumab - inhibitor receptora interleukiny 6 - nowa opcja terapeutyczna w leczeniu reumatoidalnego zapalenia stawów. Reumatologia, 2009;47:85-94
60. Świerkot J., Madej M.: Znaczenie leków biologicznych w terapii reumatoidalnego zapalenia stawów ze szczególnym uwzglȩdnieniem uzyskania remisji choroby. Czȩść I. Inhibitory czynnika martwicy nowotworów. Pol. Merkur. Lekarski, 2011;30:283-288
61. Świerkot J., Madej M.: Znaczenie leków biologicznych w terapii reumatoidalnego zapalenia stawów ze szczególnym uwzglȩdnieniem uzyskania remisji choroby. Czȩść II. Tocilizumab, Abatacept, Rituximab - leki o innych mechanizmach działania niż inhibitory TNF-a. Pol. Merkur. Lekarski, 2011;30:289-294
62. Tak P. P., Kalden J. R.: Advances in rheumatology: new targeted therapeutics. Arthritis Res. Ther., 2011;13(Suppl.1):S5
63. Takeda A. L., Colquitt J., Clegg A. J., Jones J.: Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review. Br. J. Ophthalmol., 2007;91:1177-1182
64. van de Putte L. B., Rau R., Breedveld F. C., Kalden J. R., Malaise M. G., van Riel P. L., Schattenkirchner M., Emery P., Burmester G. R., Zeidler H., Moutsopoulos H. M., Beck K., Kupper H.: Efficacy and safety of the fully human anti-tumor necrosis factor a monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann. Rheum. Dis., 2003;62:1168-1177
65. Warnke C., Menge T., Hartung H. P., Racke M. K., Cravens P. D., Bennett J. L., Frohman E. M., Greenberg B. M., Zamvil S. S., Gold R., Hemmer B., Kieseier B. C., Stüve O.: Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch. Neurol., 2010;67:923-930
66. Weger W.: Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br. J. Pharmacol., 2010;160:810-820
67. Weiner L. M., Surana R., Wang S.: Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol., 2010;10:317-327
68. Wojtukiewicz M. Z., Sierko E.: Leczenie celowane u chorych na raka jelita grubego. Onkologia w Praktyce Klinicznej, 2007;3:286-297